Esteguy M, Bonnet A M, Kefalos J, Lhermitte F, Agid Y
Rev Neurol (Paris). 1985;141(5):413-5.
Seventy parkinsonian patients (mean age: 59.6 +/- 1.2 years; duration of disease: 9 +/- 0.6 years) with severe fluctuations of disability under L-Dopa treatment received a single dose of L-Dopa (200 mg + benserazide, a peripheral decarboxylase inhibitor) after 24-72 h interruption of treatment. The delay and duration of action of a single dose of L-Dopa, and the percentage of improvement of the parkinsonian symptoms were 39 +/- 2 and 162 +/- 6 minutes, and 57 +/- 2 p. 100 respectively. Estimation of the difference between the basal parkinsonian score and the score during maximum clinical improvement under levodopa treatment, and the score under levodopa treatment may reflect the severity of dopaminergic and of non dopaminergic lesions in the brain respectively. Modification of the treatment to obtain continuous clinical improvement can be performed according to the delay and duration of action of a single dose of L-Dopa.
七十名帕金森病患者（平均年龄：59.6±1.2岁；病程：9±0.6年）在左旋多巴治疗下残疾程度严重波动，在中断治疗24 - 72小时后接受单剂量左旋多巴（200毫克+苄丝肼，一种外周脱羧酶抑制剂）治疗。单剂量左旋多巴的起效延迟时间和作用持续时间，以及帕金森病症状改善的百分比分别为39±2分钟和162±6分钟，以及57±2%。左旋多巴治疗下基础帕金森病评分与最大临床改善时评分之间的差异估计，以及左旋多巴治疗下的评分可能分别反映大脑中多巴胺能和非多巴胺能损伤的严重程度。可根据单剂量左旋多巴的起效延迟时间和作用持续时间对治疗进行调整以获得持续的临床改善。
